Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibitor of anaplastic lymphoma kinase (ALK)
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:clinical_trial |
Phase II
Phase III approximately 50% Phase I |
| gptkbp:developed_by |
gptkb:Roche
|
| https://www.w3.org/2000/01/rdf-schema#label |
alectinib
|
| gptkbp:ingredients |
C22 H24 Cl N5 O2 S
|
| gptkbp:is_atype_of |
L01 X E34
|
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Alecensa
|
| gptkbp:side_effect |
fatigue
muscle pain nausea constipation liver enzyme elevation |
| gptkbp:targets |
gptkb:ALK_gene_rearrangements
|
| gptkbp:type_of |
1195767-69-0
|
| gptkbp:bfsParent |
gptkb:ALK
|
| gptkbp:bfsLayer |
5
|